Koyfin Home > Directory > Health Care > Aimmune Therap > EV / EBITDA (ntm)

Aimmune Therap EV / EBITDA (ntm) Chart (AIMT)

Aimmune Therap annual/quarterly EV / EBITDA (ntm) from 2015 to 2016. Enterprise multiple, also known as the EBITDA multiple, is a ratio used to determine the value of a company. It uses the consensus estimate EBITA over the next twelve months (NTM). The enterprise multiple looks at a firm in the way a potential acquirer might by considering the company's debt, which other multiples such as P/E do not include.
  • Aimmune Therap EV / EBITDA (ntm) for the quarter ending May 05, 2016 was 0.25 a 2.05% increase of 0.01 year over year
  • Aimmune Therap EV / EBITDA (ntm) for the last 12 months ending May 05, 2016 was 0.25 a 2.05% increase of 0.01 year over year
  • Aimmune Therap Annual EV / EBITDA (ntm) for 2016 was 0.25 a -0.19% decrease of 0.00 from 2015
  • Aimmune Therap Annual EV / EBITDA (ntm) for 2016 was 0.25 a 3.82% increase of 0.01 from 2015
  • Aimmune Therap Annual EV / EBITDA (ntm) for 2016 was 0.24 a -1.66% decrease of 0.00 from 2015
Other Valuation Metrics:
  • Aimmune Therap Market Cap for the quarter ending March 03, 2018 was $1,841m a 43.79% increase of 806m year over year
  • Aimmune Therap Price / Book for the quarter ending March 03, 2018 was 9.15 a 57.27% increase of 5.24 year over year
  • Aimmune Therap Enterprise Value for the quarter ending March 03, 2018 was $1,659m a 52.45% increase of 870m year over year
View Chart On Koyfin

Quarterly AIMT EV / EBITDA (ntm) Data

05/20160.25
05/20160.25
05/20160.24
05/20160.25
05/20160.25
05/20160.25
05/20160.23
05/20160.22
05/20160.22
05/20160.22

Annual AIMT EV / EBITDA (ntm) Data

20160.25
20160.25
20160.24
20160.25
20160.25
20160.25
20160.23
20160.22
20160.22
20160.22